Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

详细信息    查看全文

• 作者：Lindsey H.M. te Brake^a ; ^b ; ^{Lindsey.teBrake@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author} ; Frans G.M. Russel^a ; ^{Frans.Russel@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author} ; Jeroen J.M.W. van den Heuvel^a ; ^{Jeroen.vandenHeuvel@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author} ; Gerjo J. de Knegt^c ; ^{g.deknegt@erasmusmc.nl" class="auth_mail" title="E-mail the corresponding author} ; Jurriaan E. de Steenwinkel^c ; ^{j.desteenwinkel@erasmusmc.nl" class="auth_mail" title="E-mail the corresponding author} ; David M. Burger^b ; ^{David.Burger@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author} ; Rob E. Aarnoutse^b ; ^{Rob.Aarnoutse@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author} ; Jan B. Koenderink^a ; ^{Jan.Koenderink@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Tuberculosis ; Drug-drug interactions ; ABC transporters ; Membrane vesicles ; Protein overexpression ; Vesicular transport assay
• 刊名：Tuberculosis
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：96
• 期：Complete
• 页码：150-157
• 全文大小：1140 K

文摘

Multiple-drug therapy for tuberculosis (TB) and TB-associated co-morbidity increase the likelihood of drug–drug interactions (DDIs). Inhibition of membrane transporters is an important mechanism underlying DDIs. In this study, we assessed the in vitro inhibitory potential of currently used first and second-line TB drugs and of proposed mycobacterial efflux pump inhibitors (EPIs) on the major ABC transporters relevant to drug transport, namely P-gp, BCRP, BSEP and MRP1-5.

Methods

Membrane vesicles isolated from transporter-overexpressing HEK293 cells were used to study the inhibitory action of TB drugs and EPIs on the transport of model substrates [³H]-NMQ (P-gp); [³H]-E₁S (BCRP); [³H]-TCA (BSEP); [³H]-E217βG (MRP1, 3 and 4) and [³H]-MTX (MRP2 and 5).

Results

A strong inhibition (IC₅₀ value <15 μM) was observed for clofazimine (P-gp, BCRP and MRP1), thioridazine (BCRP), timcodar (P-gp, BSEP and MRP1) and SQ109 (P-gp and BCRP). Rifampicin inhibited all transporters, but less potently.

Conclusions

Co-administration of clofazimine, thioridazine, timcodar, SQ109 and possibly rifampicin with drugs that are substrates for the inhibited transporters may lead to DDIs. The mycobacterial EPIs potently inhibited a wider range of human ABC transporters than previously reported. These vesicular transport data are especially valuable considering the current emphasis on development of TB drug regimens.